- Home
- AKA vs KRRO Comparison
AKA vs KRRO Comparison
Compare AKA & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- KRRO
- Stock Information
- Founded
- AKA 2018
- KRRO 2014
- Country
- AKA United States
- KRRO United States
- Employees
- AKA N/A
- KRRO N/A
- Industry
- AKA Catalog/Specialty Distribution
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- KRRO Health Care
- Exchange
- AKA Nasdaq
- KRRO Nasdaq
- Market Cap
- AKA 110.4M
- KRRO 147.4M
- IPO Year
- AKA 2021
- KRRO 2019
- Fundamental
- Price
- AKA $11.33
- KRRO $23.06
- Analyst Decision
- AKA Strong Buy
- KRRO Strong Buy
- Analyst Count
- AKA 3
- KRRO 7
- Target Price
- AKA $24.33
- KRRO $96.71
- AVG Volume (30 Days)
- AKA 5.4K
- KRRO 139.4K
- Earning Date
- AKA 08-06-2025
- KRRO 08-12-2025
- Dividend Yield
- AKA N/A
- KRRO N/A
- EPS Growth
- AKA N/A
- KRRO N/A
- EPS
- AKA N/A
- KRRO N/A
- Revenue
- AKA $598,107,000.00
- KRRO $6,281,000.00
- Revenue This Year
- AKA $7.23
- KRRO $97.27
- Revenue Next Year
- AKA $4.04
- KRRO N/A
- P/E Ratio
- AKA N/A
- KRRO N/A
- Revenue Growth
- AKA 7.67
- KRRO N/A
- 52 Week Low
- AKA $7.00
- KRRO $10.29
- 52 Week High
- AKA $32.25
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- AKA 53.70
- KRRO 75.47
- Support Level
- AKA $10.32
- KRRO $19.54
- Resistance Level
- AKA $11.35
- KRRO $21.63
- Average True Range (ATR)
- AKA 0.43
- KRRO 1.97
- MACD
- AKA 0.04
- KRRO 0.34
- Stochastic Oscillator
- AKA 95.53
- KRRO 92.06
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.